Phenotypes associated with this allele

• Allele Symbol: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}
• Allele Name: targeted mutation 4, Liqun Luo
• Allele ID: MGI:3716464
• Summary: 48 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo	involves: 129S1/Sv * 129X1/SvJ	MGI:3722405
cn2	Rac1^tm1Djk/Rac1^tm1Djk Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Tg(Mef2c-cre)2Blk/0	involves: 129 * BALB/c * C57BL/6 * C57BL/6J	MGI:7545527
cn3	Chd7^tm2a(EUCOMM)Wtsi/Chd7^tm2a(EUCOMM)Wtsi E2f1^Tg(Wnt1-cre)2Sor/E2f1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129 * C3H * C57BL/6 * C57BL/6N	MGI:6490654
cn4	Hprt1^tm4(CAG-Tbx18*,-Venus)Akis/Y Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Tbx18^tm4(cre)Akis/Tbx18^+	involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * NMRI	MGI:5576973
cn5	Smarca4^tm1.2Pcn/Smarca4^tm1.2Pcn Nfatc1^tm1.1(cre)Bz/Nfatc1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ	MGI:5699724
cn6	Rbfox2^tm1.1Dblk/Rbfox2^tm1.1Dblk Pax3^tm1(cre)Joe/0 Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J	MGI:7341523
cn7	Cyp11b2^tm1.1(cre)Brlt/Cyp11b2^+ Nr0b1^tm1Lja/Y Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6	MGI:5550088
cn8	Kras^tm4Tyj/Kras^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Tg(Flt3-cre)#Ccb/0	involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6	MGI:6273518
cn9	Bmp2^tm1Jfm/Bmp2^tm1Jfm Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ H2az2^Tg(Wnt1-cre)11Rth/H2az2^+	involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * CBA/J	MGI:7367250
cn10	Zfyve21^tm2c(EUCOMM)Wtsi/Zfyve21^tm2c(EUCOMM)Wtsi Tg(Cdh5-cre/ERT2)1Rha/0 Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N	MGI:7709530
cn11	Gli1^tm3(cre/ERT2)Alj/Gli1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Tnn^tm1b(KOMP)Wtsi/Tnn^tm1b(KOMP)Wtsi	involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6N	MGI:6694853
cn12	Foxg1^tm1.1(cre)Ddmo/Foxg1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1a(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu	involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N	MGI:7526487
cn13	Foxg1^tm1.1(cre)Ddmo/Foxg1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1d(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu	involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N	MGI:7526488
cn14	Foxg1^tm1.1(cre)Ddmo/Foxg1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1c(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu	involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N	MGI:7526489
cn15	Foxg1^tm1.1(cre)Ddmo/0 Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^em1Knwea/Polr1a^tm1c(EUCOMM)Hmgu	involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N	MGI:7526484
cn16	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Pfkfb3^tm1Pec/Pfkfb3^tm1Pec Tg(Cdh5-cre/ERT2)1Rha/0	involves: 129S1/Sv * 129X1/SvJ	MGI:5825525
cn17	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ H2az2^Tg(Wnt1-cre)11Rth/H2az2^+ Srsf3^tm1Pjln/Srsf3^tm1Pjln	involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J * CBA/J	MGI:7346394
cn18	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Kdm6a^tm1.1Kaig/Y Pax7^tm2.1(cre/ERT2)Fan/Pax7^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6	MGI:5779969
cn19	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^em1Knwea/Polr1a^tm1c(EUCOMM)Hmgu Tg(Wnt1-cre/Esr1*)10Rth/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N	MGI:7526471
cn20	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^em1Knwea/Polr1a^tm1c(EUCOMM)Hmgu Tg(Sox10-cre)1Wdr/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N * CBA	MGI:7526470
cn21	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj	MGI:5749858
cn22	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Hnrnpl^tm1.1Tmo/Hnrnpl^tm1.1Tmo Tg(Lck-cre)548Jxm/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:5442377
cn23	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo Tg(Mx1-cre)1Cgn/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:5517427
cn24	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Pfkfb3^tm1Pec/Pfkfb3^tm1Pec Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA	MGI:5825529
cn25	Nubp2^tm1c(EUCOMM)Hmgu/Nubp2^tm1c(EUCOMM)Hmgu Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ H2az2^Tg(Wnt1-cre)11Rth/H2az2^+ Tg(Wnt1-GAL4)11Rth/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/J	MGI:6452819
cn26	Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo Tg(MMTV-cre)4Mam/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB	MGI:5517429
cn27	Itgb1^tm1Mll/Itgb1^tm1Mll Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Tg(Nes-cre/Esr1*)1Kuan/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB	MGI:5467514
cn28	Sdhb^tm1c(EUCOMM)Hmgu/Sdhb^tm1c(EUCOMM)Hmgu Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Tg(Ins2-cre)23Herr/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J	MGI:7314957
cn29	Alx1^em1Jian/Alx1^em1Jian Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ H2az2^Tg(Wnt1-cre)11Rth/H2az2^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J	MGI:7336693
cn30	Dph1^tm1.1Cmch/Dph1^tm1.1Cmch Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ H2az2^Tg(Wnt1-cre)11Rth/H2az2^+	involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J	MGI:5659974
cn31	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1d(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Wnt1-cre/Esr1*)10Rth/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N	MGI:7526477
cn32	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1a(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Wnt1-cre/Esr1*)10Rth/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N	MGI:7526475
cn33	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1c(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Mef2c-cre)2Blk/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N	MGI:7526463
cn34	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1d(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Mef2c-cre)2Blk/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N	MGI:7526462
cn35	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1a(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Mef2c-cre)2Blk/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N	MGI:7526459
cn36	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1c(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Wnt1-cre/Esr1*)10Rth/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N	MGI:7526481
cn37	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1a(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Sox10-cre)1Wdr/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * CBA	MGI:7526465
cn38	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1d(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Sox10-cre)1Wdr/0	involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * CBA	MGI:7526466
cn39	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Smo^tm2Amc/Smo^tm2Amc Tg(Tagln-cre)1Jjl/0	involves: 129S1/Sv * 129X1/SvJ * FVB/N	MGI:5563909
cn40	Kit^tm1.1(cre)Jmol/Kit^tm2.1(cre/Esr1*)Jmol Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J	MGI:5571490
cn41	Rbfox2^tm1.1Dblk/Rbfox2^tm1.1Dblk E2f1^Tg(Wnt1-cre)2Sor/E2f1^+ Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+	involves: 129S/Sv * 129X1/SvJ * C57BL/6J	MGI:7341534
cn42	Bhlha15^tm3(cre/ERT2)Skz/? Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Trip11^tm1.1Psmi/Trip11^tm1.2Psmi	involves: 129/Sv * C57BL/6	MGI:6154165
cn43	Tg(VAV1-cre)1Graf/? Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Trip11^tm1.1Psmi/Trip11^tm1.2Psmi	involves: 129/Sv * C57BL/6	MGI:6154234
cn44	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Tg(BGLAP-cre)1Clem/? Trip11^tm1.1Psmi/Trip11^tm1.2Psmi	involves: 129/Sv * C57BL/6 * FVB/NJ	MGI:6154164
cn45	Trip11^tm1.1Psmi/Trip11^tm1.2Psmi Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Tg(Col2a1-cre)1Bhr/?	involves: 129/Sv * C57BL/6 * SJL/J	MGI:6154156
cn46	Trip11^tm1.1Psmi/Trip11^tm1.2Psmi Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/? Tg(CAG-cre/Esr1*)5Amc/?	involves: 129/Sv * C57BL/6 * SJL/J	MGI:6154270
cn47	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Pikfyve^tm2.1Tssk/Pikfyve^tm2.1Tssk Tg(Tyr-cre/ERT2)13Bos/0	involves: C57BL/6 * C57BL/6J	MGI:6256968
cn48	Gt(ROSA)26Sor^tm4(ACTB-tdTomato,-EGFP)Luo/Gt(ROSA)26Sor^+ Polr1a^tm1c(EUCOMM)Hmgu/Polr1a^tm1c(EUCOMM)Hmgu Tg(Sox10-cre)1Wdr/0	Not Specified	MGI:7526467

Genotype
MGI:3722405

hm1

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

normal phenotype

no abnormal phenotype detected ( J:124702 )

• mice are viable and fertile, with no observable adverse phenotypes

Genotype
MGI:7545527

cn2

• Allelic Composition: Rac1^tm1Djk/Rac1^tm1Djk; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Tg(Mef2c-cre)2Blk/0
• Genetic Background: involves: 129 * BALB/c * C57BL/6 * C57BL/6J

cardiovascular system

abnormal interventricular septum muscular part morphology ( J:315097 )

• at E11.5, hearts show deficient second heart field (SHF) contribution to the developing muscular interventricular septum between the right (RV) and left ventricle (LV)

• at E12.5 and E15.5, the interventricular septum has a major deficiency of SHF-derived cells, leading to formation of a bifid cardiac apex

cellular

decreased cell migration ( J:315097 )

• E12.5 right ventricle (RV) explant cultures exhibit only non-SHF-derived (mT-labeled) cells migrating from the RV explant by day 6 and very few to no SHF-derived (mG-labeled) cell migration

Genotype
MGI:6490654

cn3

• Allelic Composition: Chd7^{tm2a(EUCOMM)Wtsi}/Chd7^{tm2a(EUCOMM)Wtsi}; E2f1^{Tg(Wnt1-cre)2Sor}/E2f1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129 * C3H * C57BL/6 * C57BL/6N

mortality/aging

perinatal lethality, complete penetrance ( J:298597 )

cardiovascular system

pulmonary trunk hypoplasia ( J:298597 )

• about 5% of mutants show a hypoplastic pulmonary trunk at E15.5 and E16.5

interrupted aortic arch, type b ( J:298597 )

• about 30% of mutants exhibit interrupted aortic arch, type b at E15.5 and E16.5

abnormal conotruncal ridge morphology ( J:298597 )

• the number of neural crest cells in the proximal outflow tract cushions is reduced at E11.5

double outlet right ventricle ( J:298597 )

• all mutants exhibit the double outlet right ventricle at E15.5 and E16.5

ventricular septal defect ( J:298597 )

• all mutants exhibit a ventricular septal defect at E15.5 and E16.5

craniofacial

small frontal bone ( J:298597 )

• E17.5 mutants show a smaller frontal bone

small mandible ( J:298597 )

• E17.5 mutants exhibit a smaller mandible

small maxilla ( J:298597 )

• E17.5 mutants exhibit a smaller maxilla

abnormal pharyngeal arch morphology ( J:298597 )

• 30% of mutants show increased cell death in the pharyngeal arch region

• however, no reduction in cell proliferation is seen in the pharyngeal arch regions at E11.5

embryo

abnormal pharyngeal arch morphology ( J:298597 )

• 30% of mutants show increased cell death in the pharyngeal arch region

• however, no reduction in cell proliferation is seen in the pharyngeal arch regions at E11.5

impaired cranial neural crest cell differentiation ( J:298597 )

• marker analysis at E11.5 indicates that differentiation of cranial neural crest cells into smooth muscle cells is reduced

abnormal embryonic tissue physiology ( J:298597 )

• cell proliferation in the neural crest cell derivatives, aorta and pulmonary trunk walls, is reduced at E12.5

• 30% of mutants show increased cell death in the pharyngeal arch region

• however, no reduction in cell proliferation is seen in the dorsal neural tube, pharyngeal arch regions and outflow tract cushions at E11.5 and no increase in cell death is seen in the dorsal neural tube and outflow tract cushions at E11.5

abnormal cranial neural crest cell migration ( J:298597 )

• the number of neural crest cells in the proximal outflow tract cushions is reduced at E11.5 however, no increase in cell death or reduction in cell proliferation is seen in the outflow tract cushions, indicating that cranial neural crest cell migration to outflow tract cushions is reduced

nervous system

impaired cranial neural crest cell differentiation ( J:298597 )

• marker analysis at E11.5 indicates that differentiation of cranial neural crest cells into smooth muscle cells is reduced

skeleton

small frontal bone ( J:298597 )

• E17.5 mutants show a smaller frontal bone

small mandible ( J:298597 )

• E17.5 mutants exhibit a smaller mandible

small maxilla ( J:298597 )

• E17.5 mutants exhibit a smaller maxilla

cellular

abnormal cranial neural crest cell migration ( J:298597 )

• the number of neural crest cells in the proximal outflow tract cushions is reduced at E11.5 however, no increase in cell death or reduction in cell proliferation is seen in the outflow tract cushions, indicating that cranial neural crest cell migration to outflow tract cushions is reduced

Genotype
MGI:5576973

cn4

• Allelic Composition: Hprt1^{tm4(CAG-Tbx18*,-Venus)Akis}/Y; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Tbx18^tm4(cre)Akis/Tbx18⁺
• Genetic Background: involves: 129S1/Sv * 129S1/SvImJ * 129X1/SvJ * NMRI

cardiovascular system

abnormal epicardium development ( J:210076 )

♂ • epicardial cells exhibit premature smooth muscle cell differentiation and fail to invade into the right ventricular myocardium unlike in wild-type mice

Genotype
MGI:5699724

cn5

• Allelic Composition: Smarca4^tm1.2Pcn/Smarca4^tm1.2Pcn; Nfatc1^tm1.1(cre)Bz/Nfatc1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ

cardiovascular system

abnormal semilunar valve morphology ( J:226941 )

• semilunar valves have reduced endocardial-derived mesenchyme

• 2-fold increase in EdU-incorporated mesenchymal cells, indicating increased proliferation of cushion mesenchyme

Genotype
MGI:7341523

cn6

• Allelic Composition: Rbfox2^tm1.1Dblk/Rbfox2^tm1.1Dblk; Pax3^tm1(cre)Joe/0; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6J

embryo

embryo phenotype ( J:279139 )

N • lineage-tracing analysis showed no apparent defects in cranial and cardiac neural crest cell migration

cellular

cellular phenotype ( J:279139 )

N • lineage-tracing analysis showed no apparent defects in cranial and cardiac neural crest cell migration

Genotype
MGI:5550088

cn7

• Allelic Composition: Cyp11b2^{tm1.1(cre)Brlt}/Cyp11b2⁺; Nr0b1^tm1Lja/Y; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6

endocrine/exocrine glands

endocrine/exocrine gland phenotype ( J:204614 )

N • loss of Nr0b1 does not impact ability of zona glomerusa cells to contribute to the inner zona fasciculata even at 8 months of age; postnatal zonation and lineage conversion in the adrenal gland are normal

Genotype
MGI:6273518

cn8

• Allelic Composition: Kras^tm4Tyj/Kras⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Tg(Flt3-cre)#Ccb/0
• Genetic Background: involves: 129S1/Sv * 129S4/SvJae * 129X1/SvJ * C57BL/6

mortality/aging

premature death ( J:247853 )

• mice die at a median age of 26 days

growth/size/body

weight loss ( J:247853 )

• mice show progressive weight loss after 2 weeks of age

hepatosplenomegaly ( J:247853 )

• mice show hepatosplenomegaly after 2 weeks of age

endocrine/exocrine glands

thymus atrophy ( J:247853 )

• mice exhibit an atrophied thymus

hematopoietic system

thymus atrophy ( J:247853 )

• mice exhibit an atrophied thymus

hepatosplenomegaly ( J:247853 )

• mice show hepatosplenomegaly after 2 weeks of age

anemia ( J:247853 )

• mice show anemia after 2 weeks of age

thrombocytopenia ( J:247853 )

• mice show thrombocytopenia after 2 weeks of age

increased dendritic cell number ( J:247853 )

• mice show an increase in the frequency of CD11c+dendritic cells in the bone marrow and spleen, with expansion particularly in the atrophied thymus

• mice show histiocytic infiltrate in the spleen, liver, lung and intestines and an increase in frequency of CD11b+Gr1+ cells in the blood, bone marrow, liver, and spleen

decreased B cell number ( J:247853 )

• frequency of B220+ B lymphocytes is decreased

decreased T cell number ( J:247853 )

• frequency of CD3+ T lymphocytes is decreased

decreased double-negative T cell number ( J:247853 )

• atrophied thymus shows a deficit of CD4-CD8-CD25+ committed T cell progenitors

decreased double-positive T cell number ( J:247853 )

• atrophied thymus shows a deficit of CD4+CD8+ double-positive cells

increased leukocyte cell number ( J:247853 )

• mice show leukocytosis after 2 weeks of age

increased monocyte cell number ( J:247853 )

• mice show monocytosis after 2 weeks of age

decreased hematopoietic stem cell number ( J:247853 )

• moribund mice show a reduction hematopoietic stem cells (LSK CD150+CD48-) and multipotent progenitors (LSK CD150-CD48+) in the bone marrow and spleen

immune system

thymus atrophy ( J:247853 )

• mice exhibit an atrophied thymus

hepatosplenomegaly ( J:247853 )

• mice show hepatosplenomegaly after 2 weeks of age

increased dendritic cell number ( J:247853 )

• mice show an increase in the frequency of CD11c+dendritic cells in the bone marrow and spleen, with expansion particularly in the atrophied thymus

• mice show histiocytic infiltrate in the spleen, liver, lung and intestines and an increase in frequency of CD11b+Gr1+ cells in the blood, bone marrow, liver, and spleen

decreased B cell number ( J:247853 )

• frequency of B220+ B lymphocytes is decreased

decreased T cell number ( J:247853 )

• frequency of CD3+ T lymphocytes is decreased

decreased double-negative T cell number ( J:247853 )

• atrophied thymus shows a deficit of CD4-CD8-CD25+ committed T cell progenitors

decreased double-positive T cell number ( J:247853 )

• atrophied thymus shows a deficit of CD4+CD8+ double-positive cells

increased leukocyte cell number ( J:247853 )

• mice show leukocytosis after 2 weeks of age

increased monocyte cell number ( J:247853 )

• mice show monocytosis after 2 weeks of age

neoplasm

increased leukemia incidence ( J:247853 )

• mice develop a juvenile myelomonocytic leukemia-like disease

liver/biliary system

hepatosplenomegaly ( J:247853 )

• mice show hepatosplenomegaly after 2 weeks of age

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
juvenile myelomonocytic leukemia		DOID:0050458	OMIM:607785	J:247853

Genotype
MGI:7367250

cn9

• Allelic Composition: Bmp2^tm1Jfm/Bmp2^tm1Jfm; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺
• Genetic Background: involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J * CBA/J

craniofacial

craniofacial phenotype ( J:274818 )

N • the size of the first branchial arch is normal at E10.5

embryo

embryo phenotype ( J:274818 )

N • the size of the first branchial arch is normal at E10.5

Genotype
MGI:7709530

cn10

• Allelic Composition: Zfyve21^{tm2c(EUCOMM)Wtsi}/Zfyve21^{tm2c(EUCOMM)Wtsi}; Tg(Cdh5-cre/ERT2)1Rha/0; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ * C57BL/6N

growth/size/body

abnormal body weight ( J:350543 )

• by 3 months of age tamoxifen treated mice show increased organ weight to body weight ratios

decreased body weight ( J:350543 )

• following tamoxifen treatment at P1-P5

• difference in weight increases progressively with age reaching approximately a 40% decrease by 6 months of age

renal/urinary system

abnormal peritubular capillary morphology ( J:350543 )

• decreased junctional density in tamoxifen treated mice, possibly secondary to edema

increased glomerular capsule space ( J:350543 )

• wider spaces at 6 months of age in tamoxifen treated mice

decreased podocyte number ( J:350543 )

• modest decrease in WT-1+ podocyte densities in tamoxifen treated mice

abnormal renal glomerulus morphology ( J:350543 )

• increased glomerular volume in tamoxifen treated mice at 6 months of age

• in tamoxifen treated mice glomerular endothelial cells become swollen and subendothelial thickening is seen

abnormal glomerular endothelium fenestra morphology ( J:350543 )

• glomerular loops show reduced fenestrae in tamoxifen treated mice

abnormal kidney physiology ( J:350543 )

• expression analysis indicates reduced ENOS activity in renal microvasculature from tamoxifen treated mice at 3 months of age

abnormal renal filtration ( J:350543 )

• elevated albumin to creatinine ratio in the urine in tamoxifen treated mice

abnormal glomerular filtration barrier function ( J:350543 )

• progressive, age-related dysfunction in tamoxifen treated mice

decreased renal glomerular filtration rate ( J:350543 )

• in tamoxifen treated mice at 6 months of age

abnormal renal water homeostasis ( J:350543 )

• tubulointerstitial edema in tamoxifen treated mice

homeostasis/metabolism

increased circulating creatinine level ( J:350543 )

• in tamoxifen treated mice

decreased circulating serum albumin level ( J:350543 )

• in tamoxifen treated mice

edema ( J:350543 )

• increased wet weights of multiple tissues, including the kidneys, liver, lung, and heart in tamoxifen treated mice

cardiovascular system

abnormal glomerular endothelium fenestra morphology ( J:350543 )

• glomerular loops show reduced fenestrae in tamoxifen treated mice

abnormal peritubular capillary morphology ( J:350543 )

• decreased junctional density in tamoxifen treated mice, possibly secondary to edema

increased vascular permeability ( J:350543 )

• increased Evans Blue dye extravasation from kidney vessels in tamoxifen treated mice

Genotype
MGI:6694853

cn11

• Allelic Composition: Gli1^{tm3(cre/ERT2)Alj}/Gli1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Tnn^{tm1b(KOMP)Wtsi}/Tnn^{tm1b(KOMP)Wtsi}
• Genetic Background: involves: 129S1/Sv * 129S6/SvEvTac * 129X1/SvJ * C57BL/6N

craniofacial

abnormal tooth development ( J:302206 )

• after tamoxifen injection, lineage tracing experiments revealed differentiation and proliferation defects in the incisor stem cell compartment at 3 months of age

• GFP+ Gli1 expressing cells are decreased in number and in area in the incisor pulp, indicating decreased hedgehog signaling

• Ki67 immunostaining showed that the proliferation rate of putative mesenchymal stem cells is reduced

growth/size/body

abnormal tooth development ( J:302206 )

• after tamoxifen injection, lineage tracing experiments revealed differentiation and proliferation defects in the incisor stem cell compartment at 3 months of age

• GFP+ Gli1 expressing cells are decreased in number and in area in the incisor pulp, indicating decreased hedgehog signaling

• Ki67 immunostaining showed that the proliferation rate of putative mesenchymal stem cells is reduced

skeleton

abnormal tooth development ( J:302206 )

• after tamoxifen injection, lineage tracing experiments revealed differentiation and proliferation defects in the incisor stem cell compartment at 3 months of age

• GFP+ Gli1 expressing cells are decreased in number and in area in the incisor pulp, indicating decreased hedgehog signaling

• Ki67 immunostaining showed that the proliferation rate of putative mesenchymal stem cells is reduced

Genotype
MGI:7526487

cn12

• Allelic Composition: Foxg1^{tm1.1(cre)Ddmo}/Foxg1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1a(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}
• Genetic Background: involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N

nervous system

telencephalon hypoplasia ( J:335489 )

• in E12, E14 and E17 embryos

Genotype
MGI:7526488

cn13

• Allelic Composition: Foxg1^{tm1.1(cre)Ddmo}/Foxg1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1d(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}
• Genetic Background: involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N

nervous system

telencephalon hypoplasia ( J:335489 )

• in E12, E14 and E17 embryos

Genotype
MGI:7526489

cn14

• Allelic Composition: Foxg1^{tm1.1(cre)Ddmo}/Foxg1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1c(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}
• Genetic Background: involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N

nervous system

telencephalon hypoplasia ( J:335489 )

• in E12, E14 and E17 embryos

Genotype
MGI:7526484

cn15

• Allelic Composition: Foxg1^{tm1.1(cre)Ddmo}/0; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^em1Knwea/Polr1a^{tm1c(EUCOMM)Hmgu}
• Genetic Background: involves: 129S1/Sv * 129T/Sv * 129X1/SvJ * C57BL/6N

nervous system

telencephalon hypoplasia ( J:335489 )

• in E14 and E17 embryos

• normal in E12 embryos

Genotype
MGI:5825525

cn16

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Pfkfb3^tm1Pec/Pfkfb3^tm1Pec; Tg(Cdh5-cre/ERT2)1Rha/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ

cardiovascular system

abnormal retina vasculature morphology ( J:200070 )

• mice treated with tamoxifen at P1-4 show reduced vascular branching in retinal vessels at P5

• mice treated with tamoxifen at P1-4 show fewer distal sprouts with filopodia and fewer number of filopodia in the retinal vasculature

• distal sprouts have fewer side connections in the retinal vasculature of mice treated with tamoxifen at P1-4

• the radial expansion of the vascular plexus is reduced in mice treated with tamoxifen at P1-4

• vessel regression in the retina is increased in tamoxifen treated mice

cellular

decreased endothelial cell proliferation ( J:200070 )

• endothelial cell proliferation is reduced

vision/eye

abnormal retina vasculature morphology ( J:200070 )

• mice treated with tamoxifen at P1-4 show reduced vascular branching in retinal vessels at P5

• mice treated with tamoxifen at P1-4 show fewer distal sprouts with filopodia and fewer number of filopodia in the retinal vasculature

• distal sprouts have fewer side connections in the retinal vasculature of mice treated with tamoxifen at P1-4

• the radial expansion of the vascular plexus is reduced in mice treated with tamoxifen at P1-4

• vessel regression in the retina is increased in tamoxifen treated mice

Genotype
MGI:7346394

cn17

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺; Srsf3^tm1Pjln/Srsf3^tm1Pjln
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * BALB/c * C57BL/6J * CBA/J

embryo

decreased cranial neural crest cell apoptosis ( J:308882 )

• decreased apoptosis of cranial neural crest cells that is slight at E8.0, over 30-fold at E9.5 and 4-fold at E10.5

decreased cranial neural crest cell proliferation ( J:308882 )

• considerable at E8.0, modest at E9.5, and 4-fold at E10.5

abnormal cranial neural crest cell morphology ( J:308882 )

• reduced intensity of reporter expressing cells in the frontonasal prominence and pharyngeal arch 1 at E9.5 and throughout the facial processes at E10.5

• absence of obvious NCC streams entering the pharyngeal arches at E10.5

cellular

decreased cranial neural crest cell apoptosis ( J:308882 )

• decreased apoptosis of cranial neural crest cells that is slight at E8.0, over 30-fold at E9.5 and 4-fold at E10.5

decreased cranial neural crest cell proliferation ( J:308882 )

• considerable at E8.0, modest at E9.5, and 4-fold at E10.5

nervous system

abnormal cranial neural crest cell morphology ( J:308882 )

• reduced intensity of reporter expressing cells in the frontonasal prominence and pharyngeal arch 1 at E9.5 and throughout the facial processes at E10.5

• absence of obvious NCC streams entering the pharyngeal arches at E10.5

Genotype
MGI:5779969

cn18

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Kdm6a^tm1.1Kaig/Y; Pax7^{tm2.1(cre/ERT2)Fan}/Pax7⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6

muscle

impaired skeletal muscle regeneration ( J:232700 )

♂ • in tamoxifen-treated mice following CTX-induced muscle injury

Genotype
MGI:7526471

cn19

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^em1Knwea/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Wnt1-cre/Esr1*)10Rth/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N

mortality/aging

lethality throughout fetal growth and development ( J:335489 )

craniofacial

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

facial cleft ( J:335489 )

growth/size/body

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

facial cleft ( J:335489 )

cardiovascular system

cardiovascular system phenotype ( J:335489 )

N • normal outflow tract septation in E12 embryos

Genotype
MGI:7526470

cn20

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^em1Knwea/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Sox10-cre)1Wdr/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6N * CBA

craniofacial

midline cleft upper lip ( J:335489 )

• median lip notches in some E14-E15 embryos

cleft palate ( J:335489 )

• in some E14-E15 embryos

facial cleft ( J:335489 )

• in some E14-E15 embryos

digestive/alimentary system

cleft palate ( J:335489 )

• in some E14-E15 embryos

growth/size/body

midline cleft upper lip ( J:335489 )

• median lip notches in some E14-E15 embryos

cleft palate ( J:335489 )

• in some E14-E15 embryos

facial cleft ( J:335489 )

• in some E14-E15 embryos

Genotype
MGI:5749858

cn21

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Pdzrn3^tm1.1Ysa/Pdzrn3^tm1.1Ysa; Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/?
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * C57BL/6NCrlj * CBA * CBA/JNCrlj

vision/eye

vision/eye phenotype ( J:222522 )

N • embryos exposed to tamoxifen

abnormal retina vasculature morphology ( J:222522 )

• delayed vascularization of the superficial retinal vascular plexus at 5-12 days of age

• vessels are unstable

abnormal retina blood vessel morphology ( J:222522 )

• endothelial cell proliferation is increased

abnormal retina blood vessel pattern ( J:222522 )

• reduced vascular density and decreased number of branch points in the superficial retinal vascular plexus

• capillary network massively reduced in the deep capillary plexus

• capillary orientation in the superficial plexus relative to the deep plexus is disrupted

cardiovascular system

abnormal retina vasculature morphology ( J:222522 )

• delayed vascularization of the superficial retinal vascular plexus at 5-12 days of age

• vessels are unstable

abnormal retina blood vessel morphology ( J:222522 )

• endothelial cell proliferation is increased

abnormal retina blood vessel pattern ( J:222522 )

• reduced vascular density and decreased number of branch points in the superficial retinal vascular plexus

• capillary network massively reduced in the deep capillary plexus

• capillary orientation in the superficial plexus relative to the deep plexus is disrupted

Genotype
MGI:5442377

cn22

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Hnrnpl^tm1.1Tmo/Hnrnpl^tm1.1Tmo; Tg(Lck-cre)548Jxm/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

immune system

abnormal T cell differentiation ( J:188749 )

• T cells either do not leave thymus or fail to migrate into the blood and to the peripheral lymphoid organs

hematopoietic system

abnormal T cell differentiation ( J:188749 )

• T cells either do not leave thymus or fail to migrate into the blood and to the peripheral lymphoid organs

Genotype
MGI:5517427

cn23

• Allelic Composition: Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

hematopoietic system

abnormal common lymphocyte progenitor cell morphology ( J:202090 )

• 20-fold increase in pIpC-treated mice

increased hematopoietic stem cell number ( J:202090 )

• expanded long term hematopoietic stem-like cells in pIpC-treated mice

Genotype
MGI:5825529

cn24

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Pfkfb3^tm1Pec/Pfkfb3^tm1Pec; Tg(Pdgfb-icre/ERT2,-EGFP)1Frut/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA

cardiovascular system

abnormal retina vasculature morphology ( J:200070 )

• mice treated with tamoxifen at P1-4 show reduced vascular branching in retinal vessels at P5

• mice treated with tamoxifen at P1-4 show fewer distal sprouts with filopodia and fewer number of filopodia in the retinal vasculature

• distal sprouts have fewer side connections in the retinal vasculature of mice treated with tamoxifen at P1-4

• the radial expansion of the vascular plexus is reduced in mice treated with tamoxifen at P1-4

• vessel regression in the retina is increased in tamoxifen treated mice

cellular

decreased endothelial cell proliferation ( J:200070 )

• endothelial cell proliferation is reduced

vision/eye

abnormal retina vasculature morphology ( J:200070 )

• mice treated with tamoxifen at P1-4 show reduced vascular branching in retinal vessels at P5

• mice treated with tamoxifen at P1-4 show fewer distal sprouts with filopodia and fewer number of filopodia in the retinal vasculature

• distal sprouts have fewer side connections in the retinal vasculature of mice treated with tamoxifen at P1-4

• the radial expansion of the vascular plexus is reduced in mice treated with tamoxifen at P1-4

• vessel regression in the retina is increased in tamoxifen treated mice

Genotype
MGI:6452819

cn25

• Allelic Composition: Nubp2^{tm1c(EUCOMM)Hmgu}/Nubp2^{tm1c(EUCOMM)Hmgu}; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺; Tg(Wnt1-GAL4)11Rth/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * CBA/J

embryo

increased cranial neural crest cell apoptosis ( J:284772 )

• reduced +GFP craniofacial neural crest cells in nasal prominences and pharyngeal arches due to increased apoptosis between E9.5 and E10.5

cellular

increased cranial neural crest cell apoptosis ( J:284772 )

• reduced +GFP craniofacial neural crest cells in nasal prominences and pharyngeal arches due to increased apoptosis between E9.5 and E10.5

Genotype
MGI:5517429

cn26

• Allelic Composition: Gt(ROSA)26Sor^tm1Jus/Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}; Tg(MMTV-cre)4Mam/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB

hematopoietic system

abnormal common lymphocyte progenitor cell morphology ( J:202090 )

• 20-fold increase

increased hematopoietic stem cell number ( J:202090 )

• expanded long term hematopoietic stem-like cells

Genotype
MGI:5467514

cn27

• Allelic Composition: Itgb1^tm1Mll/Itgb1^tm1Mll; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Tg(Nes-cre/Esr1*)1Kuan/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6 * FVB

nervous system

abnormal cerebellum external granule cell layer morphology ( J:191222 )

• tamoxifen-treated mice exhibit increased number of granule cell precursors in the external granule layer

abnormal Bergmann glial cell morphology ( J:191222 )

• tamoxifen-treated mice exhibit disorganized Bergmann glial scaffolds with loose and wavy glial fibers

• endfeet of Bergmann glial fibers in tamoxifen-treated mice fail to maintain adhesion to the basement membrane unlike in control mice

ectopic cerebellar granule cells ( J:191222 )

• granule cells in tamoxifen-treated mice are trapped in the external granule layer unlike in control mice

abnormal cerebellum fissure morphology ( J:191222 )

• at P19, tamoxifen-treated mice exhibit severely compromised ingression of several fissures compared with control mice

abnormal cerebellum lobule morphology ( J:191222 )

• tamoxifen-treated mice exhibit the same lobule defects as in Ric8^tm1Zhua/Ric8^tm1Zhua Tg(GFAP-cre)25Mes mice

• however, fissural basement membrane is normal

abnormal cerebellar foliation ( J:191222 )

• tamoxifen-treated mice exhibit the same lobule defects as in Ric8^tm1Zhua/Ric8^tm1Zhua Tg(GFAP-cre)25Mes mice

Genotype
MGI:7314957

cn28

• Allelic Composition: Sdhb^{tm1c(EUCOMM)Hmgu}/Sdhb^{tm1c(EUCOMM)Hmgu}; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Tg(Ins2-cre)23Herr/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J

endocrine/exocrine glands

abnormal pancreatic beta cell physiology ( J:326592 )

• beta-cells show elevated mitochondrial membrane potential (hyperpolarization) under basal conditions that collapses upon elevated glucose exposure; this loss of mitochondrial membrane potential indicates an inability to maintain the mitochondrial electron gradient under high glucose

• acute treatment with rapamycin mitigates the hyperpolarization seen in beta-cells and the loss of mitochondrial membrane potential with high glucose exposure is rescued

Genotype
MGI:7336693

cn29

• Allelic Composition: Alx1^em1Jian/Alx1^em1Jian; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * C57BL/6N * CBA/J

embryo

embryo phenotype ( J:320497 )

N • at E9.5 and E10.5, normal patterns of GFP-labeled cranial neural crest cells (CNCCs) are seen in the frontonasal and periocular regions as well as in the branchial arches

N • at E10.5, the contribution of GFP-labeled CNCCs in the nasal, maxillary, and mandibular processes is similar to that in control embryos

Genotype
MGI:5659974

cn30

• Allelic Composition: Dph1^tm1.1Cmch/Dph1^tm1.1Cmch; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; H2az2^{Tg(Wnt1-cre)11Rth}/H2az2⁺
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6J * CBA/J

craniofacial

small nasal bone ( J:214744 )

• areas of nasal bones is reduced by about 20% at P0

skeleton

small nasal bone ( J:214744 )

• areas of nasal bones is reduced by about 20% at P0

growth/size/body

small nasal bone ( J:214744 )

• areas of nasal bones is reduced by about 20% at P0

respiratory system

small nasal bone ( J:214744 )

• areas of nasal bones is reduced by about 20% at P0

Genotype
MGI:7526477

cn31

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1d(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Wnt1-cre/Esr1*)10Rth/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N

cardiovascular system

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

persistent truncus arteriosus ( J:335489 )

• in E12 embryos

decreased heart left ventricle wall thickness ( J:335489 )

• in E12.5 embryos

increased vascular permeability ( J:335489 )

• diffuse vascular leakage in E11.5 embryos

craniofacial

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

embryo

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

growth/size/body

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

mortality/aging

lethality throughout fetal growth and development ( J:335489 )

embryonic lethality during organogenesis, complete penetrance ( J:335489 )

Genotype
MGI:7526475

cn32

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1a(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Wnt1-cre/Esr1*)10Rth/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N

cardiovascular system

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

persistent truncus arteriosus ( J:335489 )

• in E12 embryos

decreased heart left ventricle wall thickness ( J:335489 )

• in E12.5 embryos

increased vascular permeability ( J:335489 )

• diffuse vascular leakage in E11.5 embryos

craniofacial

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

embryo

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

growth/size/body

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

mortality/aging

lethality throughout fetal growth and development ( J:335489 )

embryonic lethality during organogenesis, complete penetrance ( J:335489 )

Genotype
MGI:7526463

cn33

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1c(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Mef2c-cre)2Blk/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N

cardiovascular system

ventricular septal defect ( J:335489 )

• in E12 embryos

enlarged heart ( J:335489 )

• in newborns, owing to blood pooling

heart right ventricle hypoplasia ( J:335489 )

• in E12 embryos

abnormal heart right ventricle outflow tract morphology ( J:335489 )

• shorter in E10 embryos

absent heart right ventricle ( J:335489 )

• newborn hearts have only single ventricle

growth/size/body

enlarged heart ( J:335489 )

• in newborns, owing to blood pooling

Genotype
MGI:7526462

cn34

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1d(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Mef2c-cre)2Blk/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N

cardiovascular system

ventricular septal defect ( J:335489 )

• in E12 embryos

enlarged heart ( J:335489 )

• in newborns, owing to blood pooling

heart right ventricle hypoplasia ( J:335489 )

• in E12 embryos

abnormal heart right ventricle outflow tract morphology ( J:335489 )

• shorter in E10 embryos

absent heart right ventricle ( J:335489 )

• newborn hearts have only single ventricle

growth/size/body

enlarged heart ( J:335489 )

• in newborns, owing to blood pooling

Genotype
MGI:7526459

cn35

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1a(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Mef2c-cre)2Blk/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N

cardiovascular system

ventricular septal defect ( J:335489 )

• in E12 embryos

enlarged heart ( J:335489 )

• in newborns, owing to blood pooling

heart right ventricle hypoplasia ( J:335489 )

• in E12 embryos

abnormal heart right ventricle outflow tract morphology ( J:335489 )

• shorter in E10 embryos

absent heart right ventricle ( J:335489 )

• newborn hearts have only single ventricle

growth/size/body

enlarged heart ( J:335489 )

• in newborns, owing to blood pooling

Genotype
MGI:7526481

cn36

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1c(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Wnt1-cre/Esr1*)10Rth/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N

cardiovascular system

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

persistent truncus arteriosus ( J:335489 )

• in E12 embryos

decreased heart left ventricle wall thickness ( J:335489 )

• in E12.5 embryos

increased vascular permeability ( J:335489 )

• diffuse vascular leakage in E11.5 embryos

craniofacial

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

embryo

pharyngeal arch artery hypoplasia ( J:335489 )

• in E11.5 embryos

growth/size/body

flat forehead ( J:335489 )

• starting in E9.5 embryos, worsening with age

mortality/aging

lethality throughout fetal growth and development ( J:335489 )

embryonic lethality during organogenesis, complete penetrance ( J:335489 )

Genotype
MGI:7526465

cn37

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1a(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Sox10-cre)1Wdr/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * CBA

cardiovascular system

cardiovascular system phenotype ( J:335489 )

N • normal outflow tract septation in E9.5 embryos

craniofacial

frontal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

temporal bone squamous part hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

short mandible ( J:335489 )

• in E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft palate ( J:335489 )

• in E16 and E17 embryos

facial cleft ( J:335489 )

• in E16 and E17 embryos

digestive/alimentary system

cleft palate ( J:335489 )

• in E16 and E17 embryos

growth/size/body

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft palate ( J:335489 )

• in E16 and E17 embryos

facial cleft ( J:335489 )

• in E16 and E17 embryos

respiratory system

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

skeleton

frontal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

temporal bone squamous part hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

short mandible ( J:335489 )

• in E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

Genotype
MGI:7526466

cn38

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1d(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Sox10-cre)1Wdr/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * C57BL/6N * CBA

cardiovascular system

cardiovascular system phenotype ( J:335489 )

• normal outflow tract septation in E9.5 embryos

craniofacial

frontal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

temporal bone squamous part hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

short mandible ( J:335489 )

• in E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft palate ( J:335489 )

• in E16 and E17 embryos

facial cleft ( J:335489 )

• in E16 and E17 embryos

digestive/alimentary system

cleft palate ( J:335489 )

• in E16 and E17 embryos

growth/size/body

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft palate ( J:335489 )

• in E16 and E17 embryos

facial cleft ( J:335489 )

• in E16 and E17 embryos

respiratory system

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

skeleton

frontal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

temporal bone squamous part hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

short mandible ( J:335489 )

• in E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

Genotype
MGI:5563909

cn39

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Smo^tm2Amc/Smo^tm2Amc; Tg(Tagln-cre)1Jjl/0
• Genetic Background: involves: 129S1/Sv * 129X1/SvJ * FVB/N

cardiovascular system

cardiovascular system phenotype ( J:204743 )

N • cardiopulmonary development is not disrupted

Genotype
MGI:5571490

cn40

• Allelic Composition: Kit^{tm1.1(cre)Jmol}/Kit^{tm2.1(cre/Esr1*)Jmol}; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S4/SvJaeSor * 129X1/SvJ * C57BL/6J

mortality/aging

neonatal lethality, complete penetrance ( J:210584 )

• animals die at birth, but viable fetuses are observed at E16.5 and E18.5; no Kit protein is detected by Western blot

cardiovascular system

abnormal heart development ( J:210584 )

• at E16.5, hearts have lower total numbers of EGFP-positive cells compared to controls, and no EGFP-positive cardiomyocytes

Genotype
MGI:7341534

cn41

• Allelic Composition: Rbfox2^tm1.1Dblk/Rbfox2^tm1.1Dblk; E2f1^{Tg(Wnt1-cre)2Sor}/E2f1⁺; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺
• Genetic Background: involves: 129S/Sv * 129X1/SvJ * C57BL/6J

embryo

embryo phenotype ( J:279139 )

N • lineage-tracing analysis showed no apparent defects in cranial, cardiac and enteric neural crest cell migration

cellular

cellular phenotype ( J:279139 )

N • lineage-tracing analysis showed no apparent defects in cranial, cardiac and enteric neural crest cell migration

Genotype
MGI:6154165

cn42

• Allelic Composition: Bhlha15^{tm3(cre/ERT2)Skz}/?; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Trip11^tm1.1Psmi/Trip11^tm1.2Psmi
• Genetic Background: involves: 129/Sv * C57BL/6

normal phenotype

no abnormal phenotype detected ( J:253969 )

• despite the absence of a gene invovled in vesicle transport, no swelling of the endoplasmic reticulum cisternae is found in the acinar cells of the adult pancreas

Genotype
MGI:6154234

cn43

• Allelic Composition: Tg(VAV1-cre)1Graf/?; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Trip11^tm1.1Psmi/Trip11^tm1.2Psmi
• Genetic Background: involves: 129/Sv * C57BL/6

immune system

immune system phenotype ( J:253969 )

N • normal IgG secretion

skeleton

skeleton phenotype ( J:253969 )

N • these mice, which have a hemotopoietic conditional null of a gene involved in vesicle transport, develop normally with both endochondral and intramembranous bones being of normal size and mineralization, the osteoblasts have normal Golgi apparatus stack structure and no swelling of the endoplasmic, the humeri at birth show normal trabeculae, cortical bone, and bone marrow, and micro CT measurements at 6 weeks of age are normal, so osteoblast and osteoclast function appear normal

Genotype
MGI:6154164

cn44

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Tg(BGLAP-cre)1Clem/?; Trip11^tm1.1Psmi/Trip11^tm1.2Psmi
• Genetic Background: involves: 129/Sv * C57BL/6 * FVB/NJ

cellular

abnormal Golgi stack morphology ( J:253969 )

• humeral osteoblasts have no swelling of the endoplasmic reticulum, but do have an abnormal Golgi apparatus stack structure

skeleton

skeleton phenotype ( J:253969 )

N • despite the osteoblast-specific disruption of a gene invovled in vesicle transport, these mice develop normally with both endochondral and intramembranous bones being of normal size and mineralization, and the osteoblasts having no swelling of the endoplasmic reticulum, although the osteoblast Golgi apparatus stack structure is not normal, and at 6 weeks of age micro CT measurements are normal

Genotype
MGI:6154156

cn45

• Allelic Composition: Trip11^tm1.1Psmi/Trip11^tm1.2Psmi; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Tg(Col2a1-cre)1Bhr/?
• Genetic Background: involves: 129/Sv * C57BL/6 * SJL/J

craniofacial

domed cranium ( J:253969 )

short snout ( J:253969 )

cellular

abnormal Golgi stack morphology ( J:253969 )

• loss of Golgi apparatus stacking found in humeral chondrocytes

respiratory system

impaired lung alveolus development ( J:253969 )

• histology of newborns shows decreased lung alveolar formation relative to controls, which the authors say appears to be secondary to the small ribcage

skeleton

domed cranium ( J:253969 )

decreased length of long bones ( J:253969 )

• newborn pups have shorter bones in the extremities

small thoracic cage ( J:253969 )

abnormal chondrocyte morphology ( J:253969 )

• assessment of chondrocytes in humeri finds swollen chondrocytes in some areas at E15.5 and widespread just after birth, and electron microscopy shows an increase in the size of the endoplasmic reticulum cisternae and disruption of the Golgi stack structure

chondrodystrophy ( J:253969 )

• severe

delayed bone mineralization ( J:253969 )

• newborn pups have decreased mineralization of the skull and vertebral column relative to controls

delayed endochondral bone ossification ( J:253969 )

• E15.5 humeri show delayed formation of the primary ossification center

limbs/digits/tail

short limbs ( J:253969 )

mortality/aging

perinatal lethality, complete penetrance ( J:253969 )

• although generated at the expected Mendelian frequency, these mice all die shortly after birth with severe chondrodysplasia

growth/size/body

short snout ( J:253969 )

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
achondrogenesis type IA		DOID:0080054	OMIM:200600	J:253969

Genotype
MGI:6154270

cn46

• Allelic Composition: Trip11^tm1.1Psmi/Trip11^tm1.2Psmi; Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/?; Tg(CAG-cre/Esr1*)5Amc/?
• Genetic Background: involves: 129/Sv * C57BL/6 * SJL/J

cellular

abnormal Golgi vesicle transport ( J:253969 )

• primary chondrocyte cultures treated with tamoxifen to inactivate the loxP-flanked allele have a change in the protein profile in the proteomes with many of the proteins with altered expression playing a role in membrane trafficking or Golgi/endoplasmic reticulum function, so while chondrocyte secretion continues to function the specific set of secreted proteins differs

Genotype
MGI:6256968

cn47

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Pikfyve^tm2.1Tssk/Pikfyve^tm2.1Tssk; Tg(Tyr-cre/ERT2)13Bos/0
• Genetic Background: involves: C57BL/6 * C57BL/6J

Early greying in Pikfyve^tm2.1Tssk/Pikfyve^tm2.1Tssk Tg(Tyr-cre/ERT2)13Bos/0 Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺ mice

pigmentation

diluted coat color ( J:262141 )

• after 4-OHT treatment (P21-P50) mice exhibit an early greying phenotype at P50

• however, GFP+ cells associated with hair follicles are present at P100, indicating that melanocyte survival is not significantly affected

integument

diluted coat color ( J:262141 )

• after 4-OHT treatment (P21-P50) mice exhibit an early greying phenotype at P50

• however, GFP+ cells associated with hair follicles are present at P100, indicating that melanocyte survival is not significantly affected

Genotype
MGI:7526467

cn48

• Allelic Composition: Gt(ROSA)26Sor^{tm4(ACTB-tdTomato,-EGFP)Luo}/Gt(ROSA)26Sor⁺; Polr1a^{tm1c(EUCOMM)Hmgu}/Polr1a^{tm1c(EUCOMM)Hmgu}; Tg(Sox10-cre)1Wdr/0
• Genetic Background: Not Specified

cardiovascular system

cardiovascular system phenotype ( J:335489 )

• normal outflow tract septation in E9.5 embryos

craniofacial

frontal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

temporal bone squamous part hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

short mandible ( J:335489 )

• in E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft palate ( J:335489 )

• in E16 and E17 embryos

facial cleft ( J:335489 )

• in E16 and E17 embryos

digestive/alimentary system

cleft palate ( J:335489 )

• in E16 and E17 embryos

growth/size/body

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft palate ( J:335489 )

• in E16 and E17 embryos

facial cleft ( J:335489 )

• in E16 and E17 embryos

respiratory system

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

skeleton

frontal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos

temporal bone squamous part hypoplasia ( J:335489 )

• in E16 and E17 embryos

cleft chin ( J:335489 )

• mandibular cleft in E14-E17 embryos

short mandible ( J:335489 )

• in E17 embryos

nasal bone hypoplasia ( J:335489 )

• in E16 and E17 embryos